A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD (KP415P02)
A Multicenter, Dose-Optimized, Open-Label, Safety/Tolerability and Pharmacokinetic Study With Azstarys® in Children 4 and 5 Years of Age With Attention-Deficit/Hyperactivity Disorder
Sponsor: Almac
A PHASE4 clinical study on Attention Deficit/Hyperactivity Disorder, this trial is completed. The trial is conducted by Almac and has accumulated 8 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Oct 2025 — Dec 2025 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jul 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE4
-
Sep 2024 — Jul 2025 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
▶ Show 3 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Jun 2023 — Feb 2024 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Almac
- Corium, Inc.
- Premier Research
- Prometrika, LLC
- Worldwide Clinical Trials
For direct contact, visit the study record on ClinicalTrials.gov .